Dimerix Limited announced an update for their two Phase 2 clinical studies and the opening of recruitment at Linear Clinical Research in Western Australia, following strong interest from Western Australian patients. Dimerix has two Phase 2 studies currently underway: DMX-200 for FSGS; and DMX-200 for Diabetic Kidney Disease, and is sufficiently funded to complete both studies. For both studies, some eligible patients have had to be transitioned onto Irbesartan for the required minimum 3 months period prior to entering studies, resulting in a minor impact to anticipated completion dates. This period of baseline treatment with the current standard of care treatment for both diabetic and FSGS patients is critical as it will allow the full treatment effect of DMX-200 to be observed during the study. Linear Clinical Research has been opened in Western Australia at the request of physicians and patients, and this will help enable recruitment of the remaining patients for the studies. Results are now anticipated in second quarter 2020 for both studies. DMX-200 in FSGS Phase 2a Study: Participants will receive 16 weeks propagermanium and 16 weeks placebo, separated by a 6-week washout period, during the double-blind, randomised, placebo-controlled, crossover study evaluating the safety and efficacy of DMX-200 in patients with FSGS who are receiving a stable dose of irbesartan. The FSGS Phase 2 a study is expected to complete recruitment in July 2019, with eligible patients having been identified. The first patient is expected to complete treatment in August 2019 and Dimerix will enable continued access to DMX-200 through their physician via the TGA Special Access Scheme. Study results are expected in second quarter 2020. DMX-200 in Diabetic Kidney Disease Phase 2 Study: Participants will receive 12 weeks propagermanium and 12 weeks placebo, separated by a 6-week washout period, during the double-blind, randomised, placebo-controlled, crossover study evaluating the safety and efficacy of DMX-200 in patients with diabetic kidney disease who are receiving a stable dose of irbesartan. The first diabetic kidney disease patient is expected to complete treatment in June 2019 and Dimerix will also enable continued access to DMX-200 through their physician via the TGA Special Access Scheme. The study is currently 80% recruited, and recruitment is expected to complete third quarter 2019, with study results anticipated in second quarter 2020.